. 2013 Jun;23(6):758–765. doi: 10.1089/thy.2012.0488

Table 1.

Number and Prevalence (per 1000) of Women with Liver Disease by Drug Exposure Category

	Drug exposure category^a
	MMI and/or PTU^b						No MMI or PTU
	MMI only		PTU only		MMI and PTU		TTX		No TTX		Total
	N=1201		N=1533		N=590		N=4902		N=801,375		N=809,601
Liver disease (ICD-9-CM code)	n	Prev.^c	n	Prev.	n	Prev.	n	Prev.	n	Prev.	n	Prev.
Acute and subacute necrosis (570)	1	0.83	1	0.65	0	0.00	4	0.82	143	0.18	149	0.18
Chronic liver disease and cirrhosis (571)	1	0.83	2	1.30	2	3.40	23	4.69	1591	1.99	1619	2.00
Liver abscess and sequelae (572)	0	0.00	0	0.00	0	0.00	5	1.02	99	0.12	104	0.13
Other disorders of liver (573)	4	3.34	8	5.23	0	0.00	44	8.96	2014	2.51	2070	2.56
Livers disorders in pregnancy (646.7)	0	0.00	1	0.65	0	0.00	9	1.84	642	0.80	652	0.81
Any of the above	6	5.03	10	6.54	2	3.40	70	14.24	4002	4.99	4090	5.05
Odds ratio^d	0.96		1.24		0.66		2.70
95% confidence interval^d	[0.43, 2.15]		[0.67, 2.31]		[0.17, 2.65]		[2.13, 3.42]
p-Value^d	0.924		0.500		0.559		<0.001		Ref.

^{^a}

For women with the liver disease diagnosis, drug use is at any time before the diagnosis; for women without the liver disease diagnosis, drug use is at any time during the study. Therefore, sample sizes may vary slightly across disease categories due to the time censoring of the event.

^{^b}

MMI and/or PTU categories contain 176 women with a prescription claim for MMI and/or PTU, but without a claim with a thyrotoxicosis diagnosis (ICD-9-CM 242.0 or 242.9).

^{^c}

Prevalence per 1000 women.

^{^d}

Odds ratio, 95% confidence interval, and p-value for “Any of the above” with “No TTX” as the reference group from logistic regression model adjusting for mother's age.

MMI, methimazole; PTU, propylthiouracil; TTX, thyrotoxicosis; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; Prev., prevalence; Ref., used as reference for statistical comparisons.